Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19

Fāng, Yīng; Fu, Da; Tang, Wenyi; Cai, Yu-Dong; Ma, Duan; Wang, Huijun; Xue, Ruyi; Liu, Taotao; Huang, Xiaowu; Dong, Ling; Wu, Hao; Shen, Xizhong

doi:10.1016/j.bbamcr.2012.11.020

Cited by 58 publications

(50 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HCC mortality rate is the fastest growing among all types of cancer and it is the third most common cause of tumor-associated mortality (25)(26)(27). Although there have been improvements in surgery and other therapeutic methods, the 5-year survival rate has remained <15% for a number of years (28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

Xie

Cong

Zhong³

et al. 2018

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Abstract. In order to examine the prognostic significance of miR-33a in patients with hepatocellular carcinoma (HCC), total RNA was extracted from 149 HCC biopsies, 36 of which were paired with para-carcinoma tissues, and miR-33a expression was measured by reverse transcription-quantitative polymerase chain reaction. The results demonstrated that miR-33a expression was decreased in HCC biopsies compared with normal liver tissue samples. It was also demonstrated that miR-33a expression was significantly associated with tumor foci number. Furthermore, overall and progression-free survival time was decreased in patients expressing low miR-33a with multiple tumor foci. Taken together, the low expression of miR-33a may be a potential risk factor for HCC. IntroductionHepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide, and is associated with an extremely poor prognosis (1-3). A principal reason for the high mortality of this disease is the failure of early diagnosis for patients with HCC and the lack of effective therapies for patients with HCC in advanced stages. Despite a number of advances made in therapeutic strategies and surgery, the overall prognosis for patients with HCC remains poor due to the high rate of metastasis and recurrence (4-6). Hence, the characterization of the molecular mechanisms in HCC is urgently required to allow the development of novel treatment methods for patients with HCC.MicroRNAs (miRNAs/miRs) are small non-coding RNAs (21-23 nucleotides) that are transcribed as precursors in the nucleus and are subsequently processed into mature miRNAs in the cytoplasm. Mature miRNAs primarily function by sequence specific interactions with the 3'-untranslated regions of mRNAs, leading to the translational suppression or degradation of the mRNAs (7). An increasing number of studies have suggested that miRNAs serve an essential role as prognostic and predictive biomarkers in various types of cancer. For example, miR-1290 and miR-196b have been demonstrated to predict the chemotherapeutic response of patients with lung adenocarcinoma (8). miR-149, an anti-tumor miRNA, has been identified as dysregulated in a variety of types of cancer, including gastric (9), breast (10) and colorectal cancer (11,12).It is also reported that a number of are associated with HCC carcinogenesis, progression and metastasis, including miR-15b (13), miR-122 (14) and miR-29 (15). Furthermore, the low expression of miR-124 is significantly associated with a more aggressive phenotype and a poorer prognosis (16), whereas a high expression of miR-182 has been associated with intrahepatic metastasis and poor prognosis in HCC (17). However, the mechanism of these miRNAs and their regulatory networks in HCC remain elusive, and a number of miRNAs that are associated with HCC have yet to be considered.miR-33a was originally demonstrated to regulate lipid and cholesterol metabolism (18), and is an intronic miRNA located within the sequence of the sterol regulatory element binding protein 2 (SREBP-2) gene. miR-33a ...

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

Xie

Cong

Zhong³

et al. 2018

Oncol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…Certain lysine linkages, such as lysine 48-specific linkages (UbK48) and lysine 11-specific linkages (UbK11) are linked to targeting the substrate to proteasomal degradation. Previous studies have demonstrated that UCH37 can stabilize its substrate (7,22,23). Because UCH37 is associated with the proteasome, we wanted to study whether UCH37 has an effect on E2F1 protein stability via proteasomally mediated regulation.…”

Section: Uch37 a Deubiquitinating Enzyme Interacts With E2f1 And Tmentioning

confidence: 99%

Regulation of E2 Promoter Binding Factor 1 (E2F1) Transcriptional Activity through a Deubiquitinating Enzyme, UCH37

Mahanic

Budhavarapu

Graves

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Posttranslational modifications of E2F1 alter its transcriptional activity. Results: UCH37 binds E2F1 and deubiquitinates its UbK63-specific linkages to enhance the transcriptional activation of E2F1 target genes, particularly upon DNA damage. Conclusion: Ubiquitination and deubiquitination of UbK63-specific linkages provide an additional layer of regulation for E2F1 transcriptional activity. Significance: UCH37 is the first known deubiquitinating enzyme to directly regulate E2F1.

show abstract

“…Our group found that UCH37, a novel predictor for HCC recurrence, promoted cell migration and invasion via up-regulated PRP19 (pre-mRNA processing factor 19) [75]. USP7 is also proved to be the oncoprotein in HCC which stabilizes TRIP12 (thyroid hormone receptor-interacting protein 12) and constitutively inactivates p14 [76].…”

Section: The Dubsmentioning

confidence: 97%

The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy

Chen

Shen

2016

Cancer Letters

Self Cite

View full text Add to dashboard Cite

Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19

Cited by 58 publications

References 57 publications

MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

Regulation of E2 Promoter Binding Factor 1 (E2F1) Transcriptional Activity through a Deubiquitinating Enzyme, UCH37

The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy

Contact Info

Product

Resources

About